Akagera Medicines, a Rwandan biotech company has announced promising results after completing early stages of preclinical trials of an antibiotic drug for the treatment of pulmonary tuberculosis (TB).
TB cases rise globally. New vaccine trials offer hope. Learn about TB's impact, risks, and a Dr. Alemnew Dagnew's fight for a ...
Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.
The University of Oxford has commenced a new clinical trial called TB-45, which will test tuberculosis (TB) vaccine safety ...